Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.

Xenofon Baraliakos,Atul Deodhar,Maxime Dougados,Lianne S Gensler,Anna Molto,Sofia Ramiro,Alan J Kivitz,Denis Poddubnyy,Marga Oortgiesen,Thomas Vaux,Carmen Fleurinck,Julie Shepherd-Smith,Christine de la Loge,Natasha de Peyrecave,Désirée van der Heijde

Arthritis & rheumatology (Hoboken, N.J.)（2022）

引用 5|浏览16

暂无评分

摘要

The safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The efficacy of bimekizumab in patients with AS was sustained through 3 years of treatment.

查看译文

关键词

active ankylosing spondylitis,ankylosing spondylitis,bimekizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要